A new FDA-approved combination therapy is offering hope to women with platinum-resistant ovarian cancer, a particularly aggressive form of the disease that has historically left patients with few options. The approval marks the first time an immunotherapy-based regimen has demonstrated a statistically significant survival benefit in this challenging patient population, according to the pivotal KEYNOTE-B96 trial announced in February 2026.

What Is Platinum-Resistant Ovarian Cancer and Why Is It So Difficult to Treat?

Platinum-resistant ovarian cancer develops when tumors stop responding to platinum-based chemotherapy drugs, the traditional first-line treatment for ovarian cancer. When patients experience recurrence after platinum therapy, their options become severely limited, and long-term survival rates drop significantly. This represents a critical unmet need in gynecologic oncology, affecting thousands of women who have exhausted standard treatment pathways.

The newly approved regimen combines three components: pembrolizumab (a PD-1 inhibitor that releases the brakes on immune cells), weekly paclitaxel (a chemotherapy drug that increases tumor visibility to the immune system), and bevacizumab (which cuts off blood supply to tumors). This multi-modal approach targets cancer from different angles simultaneously.

What Did the KEYNOTE-B96 Trial Actually Show?

The KEYNOTE-B96 trial enrolled adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who had received one or two prior treatment regimens. Researchers focused specifically on patients whose tumors expressed PD-L1, a protein that helps identify which patients are most likely to benefit from immunotherapy.

The results demonstrated clinically meaningful improvements for the PD-L1 positive population:

• Overall Survival: Women receiving the pembrolizumab combination lived an average of 18.2 months compared to 14.0 months in the control group, representing a 4.2-month survival extension with over 99% certainty of benefit
• Progression-Free Survival: The combination delayed disease progression to 8.3 months versus 7.2 months in the control arm, a 1.1-month difference
• Statistical Confidence: Both survival improvements reached statistical significance, meaning researchers can be highly confident these results reflect true treatment benefit rather than chance

The survival benefit represents a substantial advancement for a patient population that previously had limited therapeutic options. However, the more modest progression-free survival improvement suggests the primary benefit may come from long-term immune-mediated control of the disease rather than immediate tumor shrinkage.

How to Determine If This Treatment Is Right for You

• PD-L1 Testing Requirement: The FDA requires testing using the 22C3 pharmDx assay to identify candidates. Only patients with a Combined Positive Score of 1 or higher qualify for this regimen, meaning not all platinum-resistant ovarian cancer patients will benefit
• Treatment History Consideration: This combination is indicated for patients who have received one or two prior systemic treatment regimens and experienced platinum resistance, not for newly diagnosed patients
• Immune-Related Side Effect Monitoring: Common grade 3 or 4 adverse events include immune-mediated toxicities such as colitis, hepatitis, and pneumonitis, requiring close clinical vigilance and management by your oncology team
• Ongoing Chemotherapy Component: Pembrolizumab is used in combination with weekly paclitaxel, meaning chemotherapy remains a fundamental component of the treatment regimen rather than a standalone immunotherapy approach

Patients should discuss their PD-L1 status, treatment history, and individual clinical profile with their oncology team to determine whether this combination is appropriate for their specific situation.

What Does This Approval Mean for the Future of Ovarian Cancer Treatment?

This FDA approval underscores a significant shift toward precision medicine in gynecologic oncology. Rather than using a one-size-fits-all approach, oncologists can now identify which patients are most likely to respond based on their tumor's molecular characteristics. The requirement for PD-L1 testing ensures that patients receive targeted therapy matched to their individual cancer biology.

The approval provides a new standard of care for an otherwise difficult-to-treat population. For women with platinum-resistant disease who test positive for PD-L1, this combination offers a viable therapeutic pathway that has been shown to extend survival by over four months. While this may not sound dramatic, for patients facing recurrent ovarian cancer with limited options, additional months of life represent a meaningful clinical benefit.

One important limitation remains: the survival benefit is restricted to the PD-L1 positive population, leaving a significant gap for PD-L1 negative patients that requires further research and development of alternative therapeutic strategies.